2019
DOI: 10.1016/j.biomaterials.2019.119359
|View full text |Cite
|
Sign up to set email alerts
|

Cas9-edited immune checkpoint blockade PD-1 DNA polyaptamer hydrogel for cancer immunotherapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
52
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 68 publications
(52 citation statements)
references
References 36 publications
0
52
0
Order By: Relevance
“…These multivalent aptamers can also be incorporated with reduced graphene oxide, magnetic beads, FRET (fluorescent resonance energy transfer)‐based fluorescence molecules, or ferrocene (Figure C) for enhanced drug loading, efficient drug‐releasing or multiplexed cell imaging. Furthermore, RCA‐based multivalent aptamers could be incorporated with fluorophore‐labeled oligonucleotide or HRP for biosensors, used to prepare degradable aptamer hydrogel for cancer immunotherapy, or as an amplification strategy for aptamer SELEX . Owing to their enhanced binding affinity, size‐tunable property, exceptionally resistant ability to exonuclease degradation, and capability to circumvent multidrug resistance, multivalent aptamers from RCA have great potential for practical biomedical application.…”
Section: Rca With Functional Nucleic Acidsmentioning
confidence: 99%
“…These multivalent aptamers can also be incorporated with reduced graphene oxide, magnetic beads, FRET (fluorescent resonance energy transfer)‐based fluorescence molecules, or ferrocene (Figure C) for enhanced drug loading, efficient drug‐releasing or multiplexed cell imaging. Furthermore, RCA‐based multivalent aptamers could be incorporated with fluorophore‐labeled oligonucleotide or HRP for biosensors, used to prepare degradable aptamer hydrogel for cancer immunotherapy, or as an amplification strategy for aptamer SELEX . Owing to their enhanced binding affinity, size‐tunable property, exceptionally resistant ability to exonuclease degradation, and capability to circumvent multidrug resistance, multivalent aptamers from RCA have great potential for practical biomedical application.…”
Section: Rca With Functional Nucleic Acidsmentioning
confidence: 99%
“…The release of a programmed death receptor (PD-1) DNA aptamer promotes the activation of T-cells and reduces tumor growth. 72 Furthermore, immune checkpoint inhibitors can be released with a hydrogel-based polypeptide vaccine to improve tumor immunotherapy. Song et al developed an injectable PEG-b-poly(L-alanine) hydrogel with encapsulated granulocyte-macrophage colony-stimulating factor and anti-CTLA-4/PD-1 antibodies.…”
Section: Studying the Immunological Response In Cancer Microenvironmentsmentioning
confidence: 99%
“…PD-1 aptamer/ Immunotherapy Lee et al, 2019 Proteins Constructing an autonomous DNA robot programmed to transport payloads and present them specifically in tumors.…”
Section: Resultsmentioning
confidence: 99%
“…In the presence of ATP, the scaffold containing ATP-responsive DNA motif and its complementary single-stranded DNA was changed from duplex to tertiary aptamer structure, resulting in the release of the embedded DOX from the duplex. Additionally, as an expected immune checkpoint inhibitor, PD-1 DNA aptamers were selected to construct hydrogels containing sgRNA sequences (Lee et al, 2019). Upon exposure to Cas9/sgRNA systems, the PD-1 DNA aptamer hydrogel lost its gel properties and released the PD-1 aptamer sequence to enhance antitumor immunotherapeutic effects (Figure 1Bi).…”
Section: Stimuli-responsive Drug Deliverymentioning
confidence: 99%